JP2021533084A5 - - Google Patents
Info
- Publication number
- JP2021533084A5 JP2021533084A5 JP2020570163A JP2020570163A JP2021533084A5 JP 2021533084 A5 JP2021533084 A5 JP 2021533084A5 JP 2020570163 A JP2020570163 A JP 2020570163A JP 2020570163 A JP2020570163 A JP 2020570163A JP 2021533084 A5 JP2021533084 A5 JP 2021533084A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutical composition
- composition according
- lif
- amino acid
- Prior art date
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023187689A JP7603772B2 (ja) | 2018-06-18 | 2023-11-01 | 癌の治療に使用するためのｌｉｆ阻害剤と白金系抗悪性腫瘍剤の組み合わせ |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18382432.5 | 2018-06-18 | ||
| EP18382432 | 2018-06-18 | ||
| PCT/IB2019/000812 WO2019243900A2 (en) | 2018-06-18 | 2019-06-17 | Combination of lif inhibitors and platinum-based antineoplastic agents for use in treating cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023187689A Division JP7603772B2 (ja) | 2018-06-18 | 2023-11-01 | 癌の治療に使用するためのｌｉｆ阻害剤と白金系抗悪性腫瘍剤の組み合わせ |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021533084A JP2021533084A (ja) | 2021-12-02 |
| JP2021533084A5 true JP2021533084A5 (https=) | 2022-06-24 |
| JPWO2019243900A5 JPWO2019243900A5 (https=) | 2022-06-24 |
| JP7379390B2 JP7379390B2 (ja) | 2023-11-14 |
Family
ID=62837845
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020570163A Active JP7379390B2 (ja) | 2018-06-18 | 2019-06-17 | 癌の治療に使用するためのｌｉｆ阻害剤と白金系抗悪性腫瘍剤の組み合わせ |
| JP2023187689A Active JP7603772B2 (ja) | 2018-06-18 | 2023-11-01 | 癌の治療に使用するためのｌｉｆ阻害剤と白金系抗悪性腫瘍剤の組み合わせ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023187689A Active JP7603772B2 (ja) | 2018-06-18 | 2023-11-01 | 癌の治療に使用するためのｌｉｆ阻害剤と白金系抗悪性腫瘍剤の組み合わせ |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20210187106A1 (https=) |
| EP (1) | EP3806899A2 (https=) |
| JP (2) | JP7379390B2 (https=) |
| KR (1) | KR20210022065A (https=) |
| CN (1) | CN112955178B (https=) |
| AU (2) | AU2019291307B2 (https=) |
| CA (1) | CA3103369A1 (https=) |
| EA (1) | EA202092964A1 (https=) |
| IL (1) | IL279444A (https=) |
| MA (1) | MA52300A (https=) |
| SG (1) | SG11202012576QA (https=) |
| WO (1) | WO2019243900A2 (https=) |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| AU4231393A (en) * | 1992-05-08 | 1993-12-13 | Genentech Inc. | Antibodies to leukemia inhibitory factor |
| AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
| HU230769B1 (hu) | 1999-01-15 | 2018-03-28 | Genentech Inc. | Módosított effektor-funkciójú polipeptid-változatok |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| ES2363358B1 (es) * | 2009-04-03 | 2012-06-21 | FUNDACIÓ INSTITUT DE RECERCA HOSPITAL UNIVERSITARI VALL D'HEBRON (Titular al | Agentes terapéuticos para el tratamiento de enfermedades asociadas con una proliferación celular indeseable. |
| EP2371860A1 (en) * | 2010-04-05 | 2011-10-05 | Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron | Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation |
| CN106687134A (zh) * | 2014-09-10 | 2017-05-17 | 加利福尼亚大学董事会 | 通过抗hLIF抗体靶向K‑RAS介导的信号转导通路和恶性肿瘤 |
| CN107624071A (zh) | 2015-04-17 | 2018-01-23 | 诺福泰克公司 | 肺癌治疗方法 |
| US10583191B2 (en) * | 2016-12-19 | 2020-03-10 | Mosaic Biomedicals Slu | Antibodies against LIF and uses thereof |
| AU2019269131B2 (en) * | 2018-05-14 | 2024-02-22 | Fundació Privada Institució Catalana De Recerca I Estudis Avançats | Antibodies against LIF and dosage forms thereof |
-
2019
- 2019-06-17 MA MA052300A patent/MA52300A/fr unknown
- 2019-06-17 JP JP2020570163A patent/JP7379390B2/ja active Active
- 2019-06-17 EP EP19782687.8A patent/EP3806899A2/en active Pending
- 2019-06-17 CN CN201980053679.1A patent/CN112955178B/zh active Active
- 2019-06-17 AU AU2019291307A patent/AU2019291307B2/en not_active Ceased
- 2019-06-17 CA CA3103369A patent/CA3103369A1/en active Pending
- 2019-06-17 SG SG11202012576QA patent/SG11202012576QA/en unknown
- 2019-06-17 KR KR1020217001441A patent/KR20210022065A/ko not_active Ceased
- 2019-06-17 US US17/252,449 patent/US20210187106A1/en not_active Abandoned
- 2019-06-17 WO PCT/IB2019/000812 patent/WO2019243900A2/en not_active Ceased
- 2019-06-17 EA EA202092964A patent/EA202092964A1/ru unknown
-
2020
- 2020-12-14 IL IL279444A patent/IL279444A/en unknown
-
2023
- 2023-11-01 JP JP2023187689A patent/JP7603772B2/ja active Active
-
2024
- 2024-07-01 AU AU2024204564A patent/AU2024204564A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111182919B (zh) | 抗cd137抗体 | |
| JP2019110906A5 (https=) | ||
| RU2014138039A (ru) | Фармацевтическая композиция для лечения и/или профилактики рака | |
| RU2011111746A (ru) | Композиции рекомбинантных антител против рецептора эпидермального фактора роста | |
| HRP20180104T1 (hr) | Materijal i postupci za liječenje ili prevenciju bolesti povezanih s her-3 | |
| JP2017149720A5 (https=) | ||
| RU2014138040A (ru) | Фармацевтическая композиция для лечения и/или профилактики рака | |
| JP2018501197A5 (https=) | ||
| RU2014138038A (ru) | Фармацевтическая композиция для лечения профилактики рака | |
| CN111278861A (zh) | Pd-l1抗体、其抗原结合片段及医药用途 | |
| JP2013510868A5 (https=) | ||
| RU2014138041A (ru) | Фармацевтическая композиция для лечения и/или профилактики рака | |
| HRP20170879T1 (hr) | Genetski proizvodi koji su diferencijalno izraženi u tumorima i njihova primjena | |
| JP2024016024A5 (https=) | ||
| IL276675B1 (en) | Anti-pd-1 antibodies and uses thereof | |
| JP2021501567A5 (https=) | ||
| JP2020522512A5 (https=) | ||
| JP2021523906A5 (https=) | ||
| JP2025148452A5 (https=) | ||
| JPWO2022270524A5 (https=) | ||
| CN112041346B (zh) | 用于与抗pd-1抗体组合的抗cd137抗体 | |
| JP2021533084A5 (https=) | ||
| CN112020517B (zh) | 用于与抗pd-l1抗体组合的抗cd137抗体 | |
| JP2024023212A5 (https=) | ||
| Russell et al. | The use of epidermal growth factor receptor monoclonal antibodies in squamous cell carcinoma of the head and neck |